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ABSTRACT An increase in the incidence of rare but hard-to-treat invasive fungal
pathogens as well as resistance to the currently available antifungal drugs calls for new
broad-spectrum antifungals with a novel mechanism of action. Here we report the iden-
tiﬁcation and characterization of two novel zinc-attenuating compounds, ZAC307 and
ZAC989, which exhibit broad-spectrum in vitro antifungal activity and in vivo efﬁcacy in
a fungal kidney burden candidiasis model. The compounds were identiﬁed serendipi-
tously as part of a drug discovery process aimed at ﬁnding novel inhibitors of the fungal
plasma membrane proton ATPase Pma1. Based on their structure, we hypothesized that
they might act as zinc chelators. Indeed, both ﬂuorescence-based afﬁnity determina-
tion and potentiometric assays revealed these compounds, subsequently termed zinc-
attenuating compounds (ZACs), to have strong afﬁnity for zinc, and their growth inhibi-
tory effects on Candida albicans and Aspergillus fumigatus could be inactivated by the
addition of exogenous zinc to fungal growth media. We determined the ZACs to be fun-
gistatic, with a low propensity for resistance development. Gene expression analysis sug-
gested that the ZACs interfere negatively with the expression of genes encoding the
major components of the A. fumigatus zinc uptake system, thus supporting perturbance
of zinc homeostasis as the likely mode of action. With demonstrated in vitro and in vivo
antifungal activity, low propensity for resistance development, and a novel mode of ac-
tion, the ZACs represent a promising new class of antifungal compounds, and their ad-
vancement in a drug development program is therefore warranted.
KEYWORDS zinc homeostasis, antifungal, zinc deprivation, yeasts
The success of pathogenic microorganisms hinges upon their ability to sequesteressential nutrients from their host during infection. Through a process known as
nutritional immunity, the host immune system sequesters metals that are necessary for
microbial growth, resulting in an extremely nutrient-limited host environment (1). For
example, vertebrates express a number of iron-binding molecules, e.g., the transferrin
family, that ensure extremely low concentrations of free iron in the body (2). Addition-
ally, neutrophils and other myeloid and nonmyeloid cells synthesize large amounts of
the antimicrobial Zn2/Mn2-chelating protein calprotectin during infection, and the
contribution of calprotectin to the innate immune response against yeast and ﬁlamen-
tous fungal pathogens is well documented (3–5).
For fungal pathogens to grow and establish infection inside their hosts, they must
be able to obtain iron, zinc, and other essential metals from the harsh environment
imposed by nutritional immunity (6). Consequently, successful pathogens have evolved
elegant mechanisms to sequester essential metals from their hosts during infection.
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MECHANISMS OF ACTION:
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The mechanisms for iron sequestration are best described and include the expression
of high-afﬁnity iron transporters, iron-chelating siderophores, and iron-binding proteins
(1, 7, 8). Although iron acquisition is recognized as a virulence factor for many fungal
pathogens (7), research in recent years has highlighted the important contribution that
zinc sequestration makes to fungal pathogenesis and virulence (4, 9). Indeed, fungal
acquisition of zinc has been clearly demonstrated to be essential for fungal growth and
pathogenicity, and zinc-depleting conditions are known to reduce fungal growth in
vitro (3, 10, 11).
In all fungal species, the major zinc-binding proteins include Cu2/Zn2 superoxide
dismutases (SODs), alcohol dehydrogenase, and ribosomal proteins (12). SODs are key
enzymes in fungal virulence and are necessary for the detoxiﬁcation of reactive oxygen
species generated by host cells during fungal infection (13). In Aspergillus fumigatus,
zinc uptake is regulated by the transcriptional regulator ZafA, and deletion of zafA has
been shown to not only impair germination and overall growth capacity of A. fumigatus
in zinc-limiting media but also completely abrogate A. fumigatus virulence in a murine
model of invasive aspergillosis (11). Thus, the control of access to zinc is one of the
central battleﬁelds on which the outcome of an infection is decided. In further support
of this notion, calprotectin comprises 40% of total protein content in the neutrophil
cytoplasm during infection, and its antifungal effect can be reversed in vitro by
micromolar quantities of zinc (3, 4, 9). Because of the great need for fungal zinc uptake
during infection, it has been hypothesized that both chelation therapy and the mod-
ulation of zinc homeostasis and zinc acquisition are promising antifungal strategies
(14–18).
We have previously reported the identiﬁcation of novel antifungal compounds
targeting the fungal plasma membrane H-ATPase (19, 20). In the further optimization
process a number of compounds were synthesized, and we found two of these
compounds, ZAC307 and ZAC989, to be very potent inhibitors of Candida albicans
growth, despite the fact that they lacked H-ATPase-inhibitory activity. Due to their
characteristic arrangement of an aromatic structure with nitrogen bound in close
proximity to a hydroxyl group, we speculated that ZAC307 and ZAC989 could act as
metal chelators. Thus, the goals of this study were (i) to investigate the chelating
properties of these compounds, (ii) to characterize the spectrum of antifungal activity
of these compounds in vitro, (iii) to ascertain whether the compounds were fungistatic
or fungicidal and the propensity of C. albicans to develop resistance against these
compounds, (iv) to investigate whether the antifungal activity was caused by extracel-
lular zinc sequestration or if the compounds were taken up by Candida albicans cells,
(v) to assess whether these compounds inﬂuenced the expression level of genes
encoding zinc transporters required for zinc uptake from zinc-limiting media and that
of other genes regulated by ZafA, which is the master regulator of zinc homeostasis in
Aspergillus fumigatus, and (vi) to test and evaluate the effects of these compounds
against mammalian cells and their antifungal efﬁcacy in vivo in a murine model of
candidiasis.
RESULTS
ZAC307 and ZAC989 have high binding afﬁnity for zinc and copper but not for
magnesium and calcium. ZAC307, ZAC989, ZAC623 (collectively referred to as ZACs),
and the reference compounds EDTA and TPEN [N,N,N’,N’-tetrakis(2-pyridylmethyl)-
ethylenediamine] (Fig. 1) were evaluated for their zinc binding properties. ZAC307 and
ZAC989 have dissociation constants (Kd) in the low nanomolar range (13 to 71 nM), as
determined by a ﬂuorescence-based competition assay (Table 1). ZAC623 exhibited
poor afﬁnity for zinc, with a dissociation constant of 6 M. Dissociation constants for
EDTA and TPEN could not be determined with this assay, as they were below the
measurable range, but both have previously been reported to be very potent zinc
chelators (21).
The Zn2-binding properties of ZAC307 and ZAC989 were further evaluated using
a potentiometric assay, where pH is measured as a function of base (NaOH) added to
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the compound in either the absence or presence of metal. Since potentiometric
methods require millimolar concentrations, and ZAC307 and ZAC989 displayed poor
solubility in water at such high concentrations, the measurements were performed in
a mixture of dimethyl sulfoxide (DMSO) and water (70:30, vol/vol), as described
TPEN EDTAZAC307 ZAC989 ZAC623
A
B
ZAC307
C
ZAC989
D
ZAC623
·HCl
a b
a b c
d
e
a b c d
+
+
FIG 1 (A) Structures of the compounds ZAC307, ZAC989, ZAC623, TPEN, and EDTA. (B) Abbreviated synthetic pathway for ZAC307. (a) (i)
N-Methylmethanamine, TEA, 2-propanol, 0°C, 2 h, evaporated; (ii) hydrazine hydrate, reﬂux (block temperature, 120°C), 2 h, 65%; (b)
2-propanol, reﬂux, 1 h, 69%. (C) Abbreviated synthetic pathway for ZAC989. (a) NaH, abs. THF, 0°C, 3 h, NH4Cl, 82%; (b) diethyl ether, 0°C,
conc. HCl, quant.; (c) load onto SCX in methanol, elute with 1 M NH3 in MeOH, 95%; (d) 2-propanol, reﬂux 90 min, 14%; (e) NMP, DIPEA,
30 min at 100°C, 89%. (D) Abbreviated synthetic pathway for ZAC623. (a) tert-Butyl-N-aminocarbamate, DIPEA, THF, rt¡ reﬂux, 98%; (b)
3-[(3S)-pyrollidin-3-yl]oxypyridine-4-carbonitrile (see panel C reac. c), DIPEA, NMP, 120 °C, 1 h, 71%; (c) (i) TFA, DCM, rt, 30 min; (ii) load
onto SCX in methanol, elute with 0.5 M NH3 in MeOH, quant.; (d) Z-3-amino-but-2-enenitrile, AcOH, EtOH, 80°C 4 h, 85%.
TABLE 1 Dissociation constant determination between chelating compounds and zinca
Compound Compound-Zn2 KD (M)
ZAC989 0.013
ZAC307 0.071
ZAC623 6
EDTA 0.01
TPEN 0.01
aKd determination for the compound-Zn2 complex was performed with a ﬂuorescence-based competition
assay using FluoZin-3.
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previously (22). To determine the deprotonation constant, a solution of 1 mM ZAC307
or ZAC989 was titrated with 0.3 M NaOH at constant ionic strength (Fig. 2A and B). In
a second run, the same titration was performed in the presence of 0.5 eq of Zn2 for
ZAC307 and ZAC989. A shift in the pH curve in the presence of the metal (ZAC307, 0.5
eq of Zn2 [Fig. 2A]) compared to the absence of the metal (ZAC307 [Fig. 2A]) indicates
binding of Zn2 to the compound. The measured pH data were analyzed with the
Hyperquad program suite, taking into account all relevant equilibrium constants,
including also the constants for metal hydroxylation. The analysis provides the pKa
values and metal complex stability constants, as well as ligand-metal complex specia-
tion calculation, indicating how many ZAC molecules are involved in coordinating the
Zn2 ion at different pH values. Reﬁnement of the measured pH data for ZAC307
provided a pKa value of 6.84 and formation constants log 1, log 2, and log 3 of 7.47,
13.27, and 18.14, corresponding to the formation of 1:1, 2:1, and 3:1 ligand-Zn(II)
complexes, respectively. The corresponding species distribution diagram is displayed in
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FIG 2 Potentiometric titration results for ZAC307 and ZAC989. (A) Potentiometric equilibrium curves of ZAC307 in the absence or
presence of 0.5 mol equivalent of Zn(NO3)2, CaCl2, or MgCl2 in DMSO-water (70:30, vol/vol). (B) Potentiometric equilibrium curves
of ZAC989 in the absence or presence of 0.5 mol equivalent of Zn(CF3SO3)2, CuSO4, CaCl2, or MgCl2 in DMSO-water (70:30, vol/vol).
(C, D, and E) Species distribution diagram as a function of pH for a system containing 0.5 mM Zn(II) and 1 mM ZAC307 (C), 0.5
mM Zn(II) and 1 mM ZAC989 (D), and 0.5 mM Cu(II) and 1 mM ZAC989 (E).
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Fig. 2C, and it shows that at neutral pH in a DMSO-water solvent mixture, the
ligand-zinc stoichiometry is a mixture of 1:1, 2:1, and 3:1 binding, with 2:1 and 3:1 being
the dominant stoichiometries. Similar potentiometric experiments were carried out
with CaCl2 and MgCl2 in place of Zn(NO3)2, and these revealed that Ca2 and Mg2
binding to ZAC307 is negligible (Fig. 2A). Potentiometric titration of ZAC307 with
CuSO4 was not possible due to precipitation of the resulting complex, suggesting that
ZAC307 also binds copper. Reﬁnement of the measured pH data for ZAC989 provided
a pKa value of 7.70, and in the presence of zinc we measured formation constants log
1, log 2, and log 3 of 7.35, 14.30, and 19.71, corresponding to the formation of 1:1,
2:1, and 3:1 ligand-Zn(II) complexes, respectively (Fig. 2D). Potentiometric experiments
were also carried out with ZAC989 and CuSO4 and with CaCl2 and MgCl2, and the data
indicated that ZAC989 chelates copper, whereas binding of calcium and magnesium is
negligible. ZAC989 bound copper with the formation constants log 1, log 2, and log
3 of 7.83, 13.37, and 20.62, respectively. The most dominant ZAC989-copper stoichi-
ometry was a 3:1 stoichiometry (Fig. 2E).
ZACs are potent broad-spectrum fungistatic yeast inhibitors that work intra-
cellularly and display low potential for resistance development. ZAC307 and
ZAC989 exhibit antifungal activity and display potent growth inhibition in the low
microgram-per-milliliter range (0.2 to 0.9 g/ml) against a number of pathogenic
Candida species, including a Candida glabrata strain with increased efﬂux pump activity
(Table 2). The MIC was deﬁned as the lowest compound concentration that resulted in
at least 50% growth inhibition for yeasts, which corresponded to a prominent decrease
in visible growth. For molds the MIC was deﬁned as the lowest concentration of the
compound that resulted in no visible growth. In Candida albicans this value was 0.6
g/ml for ZAC989 and 0.4 g/ml for ZAC989. ZAC623 did not display growth-inhibitory
activity against C. albicans (Fig. 3A). The known potent metal chelators EDTA and TPEN
both exhibited a MIC of 0.05 g/ml, but TPEN led to a more complete growth
inhibition than did EDTA (Fig. 3B). The antifungal effects of ZAC989 and ZAC307 were
reversed by exogenous addition of zinc or copper to the growth medium in the
presence of either ZAC989 or ZAC307 (Fig. 3C and D). Zinc ions were most effective in
reversing the growth-inhibitory effects of the ZACs, with restoration of fungal growth
observed in the presence of 1 M Zn2. Addition of iron (Fe2) had a modest effect on
the antifungal activity of ZAC989 and ZAC307, with a fungal growth rate of approxi-
mately 50% in the presence of 100 M Fe2 compared to control cells. In accordance
with the results obtained from potentiometric titration, the addition of magnesium or
calcium had no effect on the antifungal activity of the ZACs (Fig. 3C and D).
Time-kill investigations revealed that the ZACs exhibited fungistatic activity against
C. albicans, in contrast to amphotericin B (AMB), which exhibits fungicidal activity after
3 h of exposure (Fig. 4A). Both EDTA and TPEN exhibited a fungistatic effect within the
ﬁrst 24 h of exposure. Fungal growth recovery was evaluated after longer times of
exposure of C. albicans cells to the ZACs. This revealed that the fungal cells were able
to resume growth when moved to fresh growth media in the absence of ZACs (Fig. 4B).
Fungal cells exposed to TPEN at concentrations above 2 g/ml showed poor recovery,
and this may be explained by the strong chelating properties of TPEN that enable it to
extract zinc from essential enzymes, leading to fungal cell death after prolonged
exposure (Fig. 4C).
TABLE 2MICs for several different Candida species
Compound
MIC (g/ml) for Candida isolate
C. albicans
SC5314
C. parapsilosis
ATCC 22019
C. glabrata
ATCC 90030
C. glabrata
Cg003a
C. tropicalis
Ct016
C. krusei
ATCC 6258
ZAC989 0.6 0.8 0.9 0.6 0.9 0.8
ZAC307 0.4 0.4 0.2 0.2 0.4 0.4
ZAC623 54 54 NDb ND ND 54
aThis strain has mutations resulting in increased efﬂux pump activity compared to that of wild-type isolates (34).
bND, not determined.
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In order to gain an understanding of the potential of ZACs to permeabilize into
fungal cells, we monitored the intracellular zinc levels of C. albicans cells that were
exposed to TPEN, EDTA or ZACs using the cell-permeable ﬂuorescent probe Zinbo-5.
The afﬁnity constant of this probe for zinc is 2.2 nM (23), which is weaker than that of
most zinc-binding proteins, and thus it reports only the free or weakly bound zinc ions.
The probe localizes to the internal membrane system, including the endoplasmic
reticulum (ER), in C. albicans (L. Kjellerup, A. L. Winther, D. Wilson, and A. T. Fuglsang,
submitted for publication). A decreased Zinbo-5 ﬂuorescent signal in the presence of
fungal cells, compound, and zinc would indicate that intracellular Zinbo-5 is competing
with the added compound for zinc ions. ZAC307 and ZAC989 were evaluated at a
concentration of 25 M, equivalent to 7 g/ml and 9 g/ml, respectively. ZAC989
induced a time-dependent decrease in Zinbo-5 ﬂuorescence, similarly to 1.3 g/ml of
TPEN (Fig. 4D). ZAC307 decreased the Zinbo-5 ﬂuorescence after only 1 h of incubation,
and this decrease was greater than that observed for ZAC989 (Fig. 4D), despite ZAC307
having a 5-fold-lower afﬁnity for zinc than ZAC989. These data suggested that ZAC307,
ZAC989, and TPEN were cell permeative and bound intracellular zinc. In agreement
with this, the extracellular chelator EDTA did not reduce the Zinbo-5 ﬂuorescence
under the same conditions.
We investigated the propensity for development of resistance to ZAC307 and ZAC989
by repeated exposure of C. albicans to ZACs in SDwozmedium (see Materials and Methods)
over a 36-day period. We observed no change in the MIC for the ZACs after repeated ZAC
exposure. In contrast, cells repeatedly exposed to ﬂuconazole exhibited a signiﬁcant
increase in the MIC for ﬂuconazole after 22 passages (Fig. 4E). Based on these results, it
appeared that ZAC resistance was not easily induced in C. albicans.
ZACs efﬁciently inhibit the growth capacity of Aspergillus fumigatus under
zinc-limiting conditions, and their inhibitory effects are inactivated by zinc. In
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FIG 3 (A) Candida albicans growth inhibition by ZAC989 and ZAC307 but not by the closely analogous compound ZAC623. (B) Candida
albicans growth inhibition by EDTA and TPEN. (C and D) Abrogation of the antifungal effect of ZAC989 and ZAC307 in Candida albicans
cells was achieved by the addition of Zn2 or Cu2 ions. The graphs display how much Zn2, Cu2, Fe2, Mg2, or Ca2 is required to
abrogate the antifungal effects of 1.8 g/ml of ZAC989 or 1.4 g/ml of ZAC307. C. albicans growth (expressed as percent) in panels A
to D was normalized to C. albicans growth in RPMI medium containing 1.5% DMSO. Graphs show means  SEMs for 2 or 3 independent
experiments.
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FIG 4 (A) Time-kill experiments with C. albicans revealed that ZACs exhibit fungistatic activity. The following ﬁnal
concentrations of compound were applied: 0.5 g/ml of amphotericin B (AMB), 3.6 g/ml of ZAC989, 4.4 g/ml
of EDTA, and 4.2 g/ml of TPEN. Data are means  SEMs for two biological replicates. (B and C) C. albicans cells
exposed to ZAC989 and ZAC307 for 5 days resume normal growth (B), while cells exposed to TPEN for 5 days show
poor recovery (C). C. albicans cells exposed to EDTA resumed visible growth after 48 h of compound incubation
(concentration range, 0.22 g/ml to 22 g/ml) and were therefore not evaluated for MFC. (D) A decrease in
intracellular zinc as evidenced by a decrease in Zinbo-5 ﬂuorescence signal suggests that ZAC989 and ZAC307 act
intracellularly in C. albicans. The following ﬁnal concentrations of compound were applied: 9 g/ml of ZAC989, 7
g/ml of ZAC307, 15 g/ml of EDTA, and 1.3 g/ml of TPEN. Data are means  SEMs for two biological replicates.
(E) Resistance induction study. There was no change in the MIC for the ZACs after repeated ZAC exposure, while
a signiﬁcant increase in the MIC was observed for C. albicans after 22 passages with repeated exposure to
ﬂuconazole (FLC) (1.0 g/ml).
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addition to potent antifungal effects on the ﬁve Candida species tested, ZAC307 and
ZAC989 also potently inhibited the mold Aspergillus fumigatus and other Aspergillus
species, as well a number of rare but very hard-to-treat members of the Mucorales
order, including Rhizopus oryzae, Rhizopus microsporus, and Mucor indicus. The ZACs
inhibited these molds and mucorales isolates in a range from 0.4 g/ml to 5.4 g/ml
(Table 3). To assess the capacity of the ZACs to inhibit A. fumigatus growth in the
presence of zinc, 1-ml aliquots of sRPMI zinc-limiting medium (RPMI 1640 medium
[R8755; Sigma] supplemented with 10 M FeSO4·7H2O, 1 M CuSO4·5H2O, and 1 M
MnCl2·H2O) or this medium supplemented with 2, 5, or 50 M zinc were inoculated
with 105 conidia of a wild-type A. fumigatus strain (AF14), dispensed in 24-well culture
plates, and incubated in the presence of either ZAC307 or ZAC989 at a ﬁnal concen-
tration 21 g/ml or 27 g/ml (equivalent to 75 M), respectively (Fig. 5A). Graphical
representation and quantiﬁcation of the fungal growth in 24-well culture plates in the
presence of ZACs (Fig. 5A) revealed that the growth capacity of a wild-type A. fumigatus
strain was reduced under zinc-limiting conditions but increased gradually when the
growth medium was supplemented with increasing amounts of zinc, until fungal
growth was fully restored when cultured in medium supplemented with 50 M Zn (i.e.,
under zinc-replete conditions). Hence, the inhibitory effects of the ZACs against A.
fumigatus were completely counteracted by simultaneous addition of zinc, similar to
our observations for C. albicans (Fig. 3C and D).
The zinc transporter ZrfC plays an important role in regulating fungal sensi-
tivity to the ZACs. To ascertain whether ZAC307 and ZAC989 interfered with zinc
uptake from the sRPMI zinc-limiting medium, we analyzed their effects on the growth
capacity of the mutant strains AF48 (ΔzrfA ΔzrfB), AF721 (ΔzrfA ΔzrfB ΔzrfC), AF731
(ΔzrfA ΔzrfB ΔzrfC [zrfC]), which is an AF721 derivative strain that carries the zrfC gene
reintroduced at the pyrG locus as described previously (24), and AF54 (ΔzrfC) (Fig. 5B to
E). The overall effect of the ZACs on the growth capacity of the AF48 strain was similar
to that of the wild-type strain AF14 (compare Fig. 5A and B). In the absence of ZACs,
both strains exhibited a reduced growth capacity, from 100% to 70%, when cultured in
media supplemented with 50 M compared to media supplemented with 2 M zinc.
This corresponded to a 1.4-fold reduction in growth capacity. However, in the presence
of 2 M zinc plus 75 M ZAC307, the growth capacity of AF14 and AF48 was reduced,
respectively, 2.9- and 3.9-fold compared to that in the presence of 50 M zinc. Similarly,
2 M zinc plus 75 M ZAC989 reduced the growth capacity of AF14 and AF48 3.9- and
4.5-fold, respectively. The AF721 strain did not grow under zinc-limiting conditions, and
hence the effect of these compounds on this strain could not be tested (Fig. 5C). The
reintroduction of zrfC in a strain with a ΔzrfA ΔzrfB ΔzrfC genetic background restored
the fungal growth capacity in the presence of the ZACs (Fig. 5D) at the same level as
that of the wild-type and AF48 strains (Fig. 5A and B). Finally, in the presence of 2 M
zinc either with or without simultaneous exposure to ZAC307 or ZAC989, the growth
capacity of the AF54 strain was reduced an average of 24.6-fold compared to its growth
capacity in the presence of 50 M zinc (Fig. 5E); i.e., the ZACs were between 5- and
8-fold more efﬁcient as inhibitors of the growth capacity of a ΔzrfC strain than of a
wild-type or ΔzrfA ΔzrfB strain, which suggested that the effect of ZACs could be
counteracted to a certain extent by the function of ZrfC.
ZAC307 and ZAC989 inhibit the transcription of genes regulated by ZafA under
zinc-limiting conditions. The major regulator of the A. fumigatus zinc homeostatic
response under zinc-limiting conditions is the transcription factor ZafA (11), which is a
TABLE 3MICs for several different Aspergillus and Mucorales species
Compound
MIC (g/ml) for isolate
Aspergillus fumigatus
ATCC 13073
Aspergillus ﬂavus
ATCC 15547
Aspergillus terreus
At070
Rhizopus oryzae
ATCC 34965
Rhizopus microsporus
ATCC 66276
Mucor indicus
ATCC MYA-4678
ZAC989 5.4 5.1 1.6 1.7 0.5 1.1
ZAC307 4.0 1.3 1.3 1.3 0.4 1.3
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FIG 5 Effects of ZAC307 and ZAC989 on the growth capacity of several A. fumigatus strains. (A) The wild-type AF14 strain
was cultured in 24-well culture plates inoculated with 105 conidia per well in a total volume of culture medium of 1 ml.
Culture media that were not inoculated (Ni) were used as background reference. Media were not supplemented with zinc
or were supplemented with 2, 5, or 50 M ZnSO4 in the absence () or the presence () of ZAC307 (Z7) or ZAC989 (Z9),
as indicated. Plates were incubated at 37°C in a humid atmosphere for 44 h, scanned, and quantiﬁed, and the growth was
represented graphically. (B) Effect of ZACs on the growth capacity of the ΔzrfA ΔzrfBmutant strain (AF48). (C) Effect of ZACs
on the growth capacity of the ΔzrfA ΔzrfB ΔzrfC mutant strain (AF721). (D) Effect of ZACs on the growth capacity of the
ΔzrfA ΔzrfB ΔzrfC (zrfC) mutant strain (AF731). (E) Effect of ZACs on the growth capacity of the ΔzrfC mutant strain (AF54).
The AF48, AF721, AF731, and AF54 strains were all cultured and incubated in 24-well culture plates, and their growth was
(Continued on next page)
Antifungal Zinc-Attenuating Compounds Antimicrobial Agents and Chemotherapy
May 2018 Volume 62 Issue 5 e02024-17 aac.asm.org 9
 o
n
 July 19, 2018 by KB, Københavns Universitetsbibliotek
http://aac.asm
.org/
D
ow
nloaded from
 
zinc-responsive factor that senses the intracellular concentration of zinc in a way similar
to that of its orthologue Zap1 in the yeast Saccharomyces cerevisiae (25). Thus, when the
cytoplasmic zinc content is high enough, ZafA becomes saturated with Zn2 ions and
adopts a transcriptionally inactive conformation. In contrast, when the intracellular
concentration drops below a certain threshold, ZafA begins to release Zn2 ions and
gradually adopts a transcriptionally active conformation, whereby it is able to induce
the expression of zrfA and zrfB in acidic zinc-limiting media and of zrfC in alkaline
zinc-limiting media (11, 24).
We employed quantitative reverse transcription-PCR (RT-qPCR) to assess whether
exposure to ZAC307, ZAC989, EDTA, or TPEN inﬂuenced the expression of several ZafA
target genes and other genes not regulated directly by ZafA (as controls) (Table 4). The
set of genes investigated was selected based on a genome-wide transcription analysis
of A. fumigatus grown under zinc-limiting conditions that had been performed previ-
ously in our laboratory (J. A. Calera, unpublished data), using the primers listed in Table
5. All selected ZafA target genes were induced by ZafA under zinc-limiting conditions
with the exception of the putative zinc storage vacuole transporter zrcA, which was
repressed by ZafA under zinc-limiting conditions (Calera, unpublished). As expected,
the relative expression levels of all ZafA target genes induced by ZafA under zinc-
limiting conditions were dramatically reduced, to almost undetectable levels, upon the
addition of Zn2 (Fig. 6). In contrast, the expression level of the zrcA gene, which was
repressed by ZafA, and most of the genes not regulated by ZafA increased under
zinc-replete conditions to different extents, with the exception of actA, whose expres-
sion level remained similar to that observed before the zinc shock. Interestingly,
exposure to either ZAC307 or ZAC989 inhibited the expression of the ZafA target genes
similarly. We also observed reduced expression levels for most of the investigated
genes that were not regulated by ZafA following ZAC307 exposure. In particular, the
expression level of pmaA, which encodes the orthologue of the Pma1 H-ATPase from
S. cerevisiae, and that of the gdpA and tubB1 genes were reduced at levels similar to that
of the ZafA target genes (Fig. 6). In contrast, treatment with ZAC989 did not have a
noticeable effect on the expression levels of the genes not regulated by ZafA, which
remained similar to that observed under zinc-limiting conditions (Fig. 6). This ﬁnding
suggested that although the overall outcomes of the treatment with ZAC307 and
ZAC989 on ZafA-regulated genes were quite similar, the precise mode of action of
FIG 5 Legend (Continued)
quantiﬁed as described for the wild-type strain. In all cases the relative arbitrary units obtained after quantiﬁcation of the
plates were normalized by taking the average of the background values of cultures which were not inoculated as a growth
capacity of 0% and the growth reached by the wild-type strain in media supplemented with 50 M zinc in the absence
of ZACs as a growth capacity of 100%. In all graphs, the data represent the averages and SDs from two independent
experiments in which all strains had been cultivated in duplicate.
TABLE 4 Selected genes for quantifying relative expression level by RT-qPCR
Regulation by ZafA Gene Code Function
Regulated zafA AFUA_1G10080 Major transcriptional regulator of zinc homeostasis
zrfB AFUA_2G03860 Zinc transporter of the ZIP family putatively located in the cytoplasmic membrane
zrfC AFUA_4G09560 Zinc transporter of the ZIP family putatively located in the cytoplasmic membrane
zrfF AFUA_2G08740 Zinc transporter of the ZIP family putatively located in vacuolar membrane
zrcA AFUA_7G06570 Zinc transporter of the CDF family putatively located in vacuolar membrane
mchC AFUA_8G02620 Putative zinc metallochaperone
sarA AFUA_7G06810 Putative L-amino acid oxidase
Not regulated actA AFUA_6G04740 Actin
tubB1 AFUA_1G10910 -Tubulin subunit 1
gdpA AFUA_5G01970 Glyceraldehyde-3-phosphate dehydrogenase
pmaA AFUA_3G07640 Plasma membrane H-ATPase
mchA AFUA_2G11720 Putative metallochaperone
mchB AFUA_4G07990 Putative metallochaperone
Cohrt et al. Antimicrobial Agents and Chemotherapy
May 2018 Volume 62 Issue 5 e02024-17 aac.asm.org 10
 o
n
 July 19, 2018 by KB, Københavns Universitetsbibliotek
http://aac.asm
.org/
D
ow
nloaded from
 
ZAC307 on gene expression was different from that of ZAC989, which appeared to
inhibit the ZafA regulated genes more speciﬁcally than ZAC307.
Finally, we anticipated that chelation of extracellular zinc upon addition of a
relatively high concentration of EDTA to the culture media for a short period (2 h)
would result in a transient hyperactivation of ZafA and concomitant upregulation of the
most direct ZafA target genes, including those encoding zinc transporters. We expected
to observe the same effect with TPEN treatment, although in this case chelation of
intracellular zinc should exacerbate the zinc starvation status of the fungal cells, leading
to a more extended hyperactivation of ZafA and higher expression of the ZafA target
genes than attained with EDTA after the same incubation period. The expression proﬁle
for the ZafA-regulated genes observed in EDTA- or TPEN-treated cultures reﬂected
precisely what we predicted (Fig. 6).
In summary, these results suggested that the antifungal effects of ZAC307 and
ZAC989 were most likely mediated through a mechanism that ultimately results in the
inhibition of the transcriptional activation activity of ZafA.
Cytotoxicity and off-target activity studies. ZAC307, ZAC989, EDTA, and TPEN
were evaluated for mammalian cytotoxicity in a standard hepatocyte proliferation
assay, where the mammalian HepG2 cell line was exposed to the compounds for either
24 h or 72 h. After 24 h of exposure to ZAC307 and ZAC989, the half-maximal effective
concentration (EC50) was 28 g/ml, while after 72 h of exposure, the EC50s were 13.2
g/ml and 6.9 g/ml, respectively (Table 6). With antifungal activity against yeast and
the Mucorales isolates in the 0.2- to 1.7-g/ml range, the compounds exhibited a
reasonable selectivity index toward mammalian cells. However, the selectivity index
between the Aspergillus species and mammalian cells was limited. The nonpermeative
chelator EDTA did not affect the proliferation of HepG2 cells, while the potent zinc
chelator TPEN had an EC50 of 1.6 g/ml after 24 h of exposure.
ZACs exhibited in vivo efﬁcacy in a murine fungal kidney burden candidiasis
model. ZAC989 and ZAC307 were investigated for in vivo efﬁcacy in a fungal kidney
burden model (Fig. 7; Table 7). In this model, BALB/c mice were infected intraperito-
TABLE 5 Primers used to quantify mRNA by RT-qPCR
Oligonucleotide Sequence (5= ¡ 3=)
18SRNA-D TGTTAAACCCTGTCGTGCTG
18SRNA-R GTACAAAGGGCAGGGACGTA
ZAFA- D1 GGCAAGTCATTTACCGACAGC
ZAFA-R1 TCGATGACTTGACATGTTGGACG
ZRFB-D ACCGGCAGAAGAAGCATTGA
ZRFB-R ACCGCATCACCATCAACTCA
ZRFC-D CAAACTCTCGGTGCTCGTCA
ZRFC-R GAAGACAATCACCACCAGCA
qZRFF2-D CGTATTCCCTCTCATGTCGTCG
qZRFF2-R AGAGCCATTTGCCTGGTTCG
SARA-D GCATATCATGTCACCGAGCACA
SARA-R AGCCCCAACTCCAACAACAA
qMCHC-D CATGCTAACGATGGGATGCG
qMCHC-R CTTCGGTCTCCCAATGGTGG
qZRCA-D TGCAGAGTGTTCCTCTCGGAGTCG
qZRCA-R TCGCCAGATATGCAGTTCATGGACG
qACT3-D CCACGTCACCACTTTCAACTCCATC
qACT3-R TCCTTCTGCATACGGTCGGAGATAC
qGDPA2-D CTCACTTGAAGGGTGGTGCC
qGDPA2-R GATGTCGGAGGTGTAGGTGG
qPMA12-D AGATCGCTACTCCTGAGCACG
qPMA12-R CTTCTGCTCGGCAAGGTAAGC
BTUB-D AACAACATCCAGACCGCTCT
BTUB-R TGATCACCGACACGCTTGAA
qMCHA-D GAAACCGCAACGAGCCATAC
qMCHA-R ACGAGATCCGCCTTGTTCAG
qMCHB-D TGATCTTGAGGTGCAGACGC
qMCHB-R TGATGGTCATCCGTCAACCG
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neally (i.p.) on day 0. Initially, administration of ZACs included a pretreatment 24 h prior
(day 1) to infection (day 0) by the i.p. route. The mice were then treated with either
ZAC for 4 days (day 1 to day 2) to maximize the likelihood of observing in vivo
efﬁcacy. The endpoint was mean log CFU in the kidneys of treated animals compared
to the value for untreated animals. Fluconazole was chosen as a comparator compound
and dosed per os (p.o.), and treatment with ﬂuconazole resulted in a signiﬁcant
reduction in kidney burden, 2.78 log CFU/kidney (Fig. 7). The in vivo studies also
revealed that i.p. dosing of ZAC989 at 60 mg/kg of body weight resulted in a
statistically signiﬁcant reduction, 1.71 log CFU/kidney, while ZAC307 administration at
60 mg/kg led to a signiﬁcant reduction, 1.06 log CFU/kidney. ZAC307 yielded equal in
vivo efﬁcacies with and without pretreatment (Fig. 7; Table 7). We observed no adverse
effects following dosing of 60 mg/kg of ZAC307, but for ZAC989, we observed lethargy
lasting for 5 to 15 min after dosing.
DISCUSSION
During this study, we identiﬁed a new series of zinc-attenuating compounds with
broad-spectrum antifungal activity in vitro and in vivo activity in a candidiasis fungal
kidney burden model. The compounds ZAC307 and ZAC989 possess a characteristic
arrangement of an aromatic structure with nitrogen bound in close proximity to a
hydroxyl group. This structural arrangement led us to speculate whether ZAC307 and
ZAC989 were metal chelators. To address this hypothesis, we synthesized ZAC623 as a
FIG 6 Effects of the ZACs, the extracellular chelator EDTA, and the intracellular chelator TPEN on the
transcription of ZafA target genes under zinc-limiting conditions. The wild-type strain precultured in the
sRPMI zinc-limiting medium for 20 h at 37°C with shaking at 200 rpm was left untreated (Zn) or treated
with 20 M zinc (Zn), 21 g/ml of ZAC307 (ZAC307), 27 g/ml of ZAC989 (ZAC989), 146 g/ml of
EDTA (EDTA), and 10.6 g/ml TPEN (TPEN). The expression level of the indicated genes was analyzed
by RT-qPCR using 18S rRNA as an internal reference. The changes in the relative expression ratios (rER) were
measured after 2 h of incubation following treatment with the different compounds and compared to the
expression levels observed under zinc-limiting conditions (Zn). The bar diagram depicts the averages and
SDs of the results obtained in two independent experiments.
TABLE 6 In vitro cell proliferation assay with HepG2 cells
Compound
EC50 (g/ml)
24 h 72 h
ZAC989 36 6.9 0.7
ZAC307 28 13.2 0.8
EDTA 29 29
TPEN 1.6 0.2 1.4 0.8
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control compound where the hydroxyl group is replaced with an amino group, and as
expected, this compound lacked metal-chelating and antifungal properties (Fig. 1 and
3A; Table 1). The metal-chelating compounds EDTA and TPEN have previously been
described as antifungal compounds (16, 17, 26); thus, they were selected as compar-
ators in this study.
Our ﬁndings indicate that ZAC307 and ZAC989 chelate both zinc and copper, with
zinc ions being most effective in reversing the growth-inhibitory effects of the ZACs
(Fig. 3C and D). The ZACs have lower afﬁnity for iron and negligible afﬁnity for
magnesium and calcium. The ZACs are less potent zinc chelators than the known zinc,
copper, and iron chelators TPEN and EDTA, but they inhibit fungal growth more
effectively than EDTA (Fig. 3A and B). The inhibitory effects of the ZACs can be
inactivated by the addition of excess zinc in both Candida albicans and Aspergillus
fumigatus, which indicates that these compounds interfere either directly or indirectly
with fungal zinc homeostasis.
The ﬁrst challenge that any microorganism faces in the homeostatic response to zinc
deﬁciency is to obtain zinc from the surrounding environment. The major components
of the zinc uptake system in A. fumigatus that facilitates zinc uptake from zinc-limiting
media are the ZIP plasma membrane transporters ZrfA, ZrfB, and ZrfC. The ZrfA and ZrfB
transporters operate mainly under acidic zinc-limiting conditions (27), although they
also contribute to zinc uptake from alkaline zinc-limiting media along with ZrfC (3),
which is expressed exclusively in alkaline media (24). Therefore, we reasoned that if the
ZACs inhibited the intake of zinc mediated by these transporters, the growth capacity
of a wild-type strain in the presence of ZACs should be reduced to the same level as
that of fungal mutant strains lacking the acidic (ZrfA and ZrfB) and/or the alkaline (ZrfC)
zinc transporter. The investigation of the growth capacity of a ΔzrfC mutant in the
presence of the ZACs suggested that ZrfC plays an important role in overcoming ZAC
inhibition, since deletion of zrfC increased the sensitivity of A. fumigatus to these
compounds (AF14 versus AF54 [Fig. 5A and E]). Hence, it could be possible that the
2
FIG 7 In vivo efﬁcacy data for ZAC989 and ZAC307 in a 3-day candidiasis kidney burden model. Dosing
with and without pretreatment (day 1) yields the same CFU reduction for ZAC307. #, no pretreatment
in this arm; *, P  0.05 compared to infected untreated control group by one-way analysis of variance
(ANOVA).
TABLE 7 Fungal kidney burden candidiasis in vivo model
Parameter
Value with antifungal therapya
None
(untreated control)
Fluconazole,
3 mg/kg
ZAC989,
60 mg/kg
ZAC307,
60 mg/kg
ZAC307, 60 mg/kg,
no pretreatment
Mean log CFU/kidney 5.79 0.14 3.02 0.22 4.09 0.31 4.73 0.19 4.77 0.19
Mean log CFU/kidney reduction NA 2.78* 1.71* 1.06* 1.03*
a*, P  0.05 compared to infected vehicle control group, one-way ANOVA. NA, not applicable.
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actual effect of ZACs on the ΔzrfA ΔzrfB strain was masked to some extent by the ZrfC
function. As expected, the AF721 strain lacking zrfC did not grow under zinc-limiting
conditions, and the effects of these compounds on this strain could therefore not be
tested (Fig. 5C). However, we observed that ZAC989 noticeably inhibited the growth
capacity of AF721 in the presence of 50 M zinc. Thus, it is plausible that ZAC989
interfered with a zinc homeostatic process other than zinc uptake. Furthermore, the
higher growth capacity of the ΔzrfC strain in the absence of ZACs than of the wild-type,
AF48, or AF731 strain suggested that the lack of zrfC in AF54 may have been compen-
sated for by the overexpression of zrfA and zrfB, as reported previously (3). On the other
hand, the stronger growth inhibition of the growth capacity of the AF54 strain in the
presence of ZAC307 and ZAC989 than of the wild-type, AF48, or AF731 strain suggested
that the levels of expression of the zrfA and zrfB genes in AF54 were insufﬁcient to
counteract the effects of ZAC307 and ZAC989. Taken together, these results suggest
that both ZAC307 and ZAC989 interfered negatively with the expression of the genes
encoding zinc transporters rather than with their zinc uptake function. Indeed, gene
expression analysis by RT-qPCR suggested that the antifungal effects of ZAC307 and
ZAC989 were mediated through a mechanism that ultimately results in inhibition of the
transcriptional activation activity of ZafA. In addition, and since ZafA activity was
inactivated by zinc under physiological conditions, the effects of ZAC307 and ZAC989
on the expression of ZafA-regulated genes could be exerted either directly, upon their
binding to ZafA, or indirectly by increasing the cytosolic concentration of Zn2 ions
that would bind to and inactivate ZafA. Although direct binding of ZAC307 or ZAC989
to ZafA was an attractive possibility, we consider it more likely that the ZACs triggered
a transient rise in the cytosolic concentration of Zn2 ions by favoring their releasing
from cytosolic zinc ligands and/or zinc storage compartments (e.g., the vacuole). For
the data presented in Fig. 4D, we observed that the ZACs promote a decrease in the
available zinc levels within the internal membrane system, including the ER, in C.
albicans. This decrease can be explained either by a direct competition between
Zinbo-5 and ZACs within these compartments or by promotion by the ZACs of the
release of zinc from the ER into the cytosol. The latter scenario could induce a higher
concentration of zinc in the cytosol, and if the same situation occurs in A. fumigatus, this
could explain the decrease in transcription of the ZafA-induced genes, similar to when
zinc is added extracellularly. Moreover, since most intracellular eukaryotic zinc proteins
bind zinc with a higher afﬁnity than ZACs (Kd values for most zinc-binding proteins are
between 0.1 and 1.0 pM) (28), it is more likely that these compounds interfere with the
regulation of zinc homeostasis by promoting the release of Zn2 ions from intracellular
storage compartments. Nevertheless, since acidiﬁcation of cytoplasm can also promote
zinc release from cytoplasmic zinc ligands (29), it could also be possible that the ZACs
disturbed the activity of proteins involved in maintaining the pH homeostasis of the
cytoplasm. In this regard, we observed that the expression level of pmaA was higher
under zinc-replete than under zinc-limiting conditions. This ﬁnding suggests a putative
interplay between the function of PmaA and the Zn2 transport capacity of the fungal
zinc transporters, provided that the expression level of the pmaA gene correlated with
the H-ATPase (PmaA) activity. It is known that the accumulation of zinc into the
vacuole by CDF transporters (e.g., ZrcA) is mediated through a Zn2/H antiporter
mechanism and relies on the proton gradient generated by the V-ATPase (30). In
contrast, and although it is not completely known how ZIP proteins transport zinc
across the plasma membrane, it seems that it is not dependent on the proton gradient
generated by the plasma membrane H-ATPase but is pH dependent, such that
intracellular acidiﬁcation increases zinc transport, whereas extracellular acidiﬁcation
decreases zinc transport (31–33). In this regard, it is plausible that under the alkaline
zinc-limiting conditions provided by sRPMI medium, a low PmaA activity would in-
crease intracellular acidiﬁcation to favor zinc uptake by ZIP transporters located in the
plasma membrane. In contrast, a high PmaA activity under zinc-replete conditions
would reduce intracellular acidiﬁcation and increase extracellular acidiﬁcation (e.g., to
counteract the Zn2-induced dissipation of the electrochemical gradient that is essen-
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tial for fungal survival). The same reasoning could be applied to zinc transport by the
ZrfF ZIP transporter located in the vacuolar membrane, such that the intravacuolar pH,
which is kept lower than the cytosolic pH under normal conditions via V-ATPase
activity, would favor the exit of Zn2 ions into the cytosol. However, the unexpected
ﬁnding that ZAC307 reduces pmaA expression suggested that it might interfere with
the putative mechanism that links the regulation of zinc homeostasis with the function
of PmaA.
The ZACs display broad-spectrum fungistatic activity and exhibit a low propensity
for acquired resistance development compared to that of ﬂuconazole. Additionally,
they are superior antifungal agents to the nonpermeative chelator EDTA, and our
RT-qPCR data suggest that the ZACs affect fungal zinc homeostasis differently from the
very potent chelator TPEN. Therefore, the ZACs act distinctly from either EDTA or TPEN,
both of which have previously been investigated as antifungal agents. EDTA has been
evaluated as a combination treatment together with amphotericin B lipid complex
(ABLC) in an invasive pulmonary aspergillosis model in immunosuppressed rats. The
combination of EDTA with ABLC led to improved survival times and a lower tissue
burden of A. fumigatus than with either agent alone (26). Furthermore, TPEN has been
shown to signiﬁcantly increase survival after 7 days compared to that with vehicle
treatment in a murine model of invasive pulmonary aspergillosis (16). Moreover,
administration of either of the two zinc-chelating agents phenanthroline and TPEN has
been shown to lead to signiﬁcant improvements in survival with concomitant reduction
in fungal burden in immunosuppressed mice intranasally infected with A. fumigatus.
Finally, it was shown that TPEN given in combination with caspofungin signiﬁcantly
increased survival times in murine models of invasive aspergillosis compared to that
with either drug alone (17).
There is an unmet need for novel antifungal agents with broad-spectrum antifungal
activity and low potential for resistance development for the treatment of invasive
fungal infections. With potent antifungal activity both in vitro and in vivo, the ZACs
fulﬁll these criteria, and their advancement in a drug development program is therefore
warranted. Interestingly, the ZACs and EDTA did not inhibit mammalian cell prolifera-
tion considerably within the ﬁrst 24 h of exposure (EC50  28 g/ml), in contrast to
TPEN (EC50 1.6 g/ml), and even after 72 h of ZAC exposure, we observed a12-fold
selectivity index in growth inhibition between C. albicans and HepG2 cells; the index
between A. fumigatus and HepG2 cells was limited. However, it should be taken into
account that metal ions are crucial in every cellular system, including the host.
Therefore, any intervention aiming to treat an infection through ion sequestration must
deal with the delicate balance between positive and negative effects in both the
pathogen and the host. The therapeutic safety window as well as whether the ZACs can
induce zinc deﬁciency in the host still needs to be addressed. In summary, interfering
with fungal zinc-dependent processes represents a promising new approach to anti-
fungal therapy, and this series of zinc-attenuating compounds represents a potentially
new class of antifungal agents.
MATERIALS AND METHODS
Synthesis of ZAC307, ZAC989, and ZAC623. ZAC307 {2-[6-(dimethylamino)pyrimidin-4-yl]-
5-phenyl-pyrazol-3-ol} synthesis pathway: (a) (i) N-methylmethanamine, TEA, 2-propanol, 0°C, 2 h,
evaporate, (ii) hydrazine hydrate, reﬂux, 2 h, column chromatography, yield 65%; (b) ethyl 3-oxo-3-
phenyl-propanoate-2-propanol, reﬂux, 1 h, yield: 69%, 1H nuclear magnetic resonance (NMR) (400 MHz;
DMSO-d6, d): 13.2 (1H, bs), 8.49 (1H, d), 7.89 (2H, bd), 7.43 (3H, m), 6.92 (1H, bs), 6.13 (H, s), and 3.17 (6H, s).
ZAC989 {3-[(3S)-1-[6-(5-hydroxy-3-methyl-pyrazol-1-yl)pyrimidin-4-yl]pyrrolidin-3-yl]oxy-pyridine-
4-carbonitrile} synthesis pathway: (a) NaH, abs. tert-butyl (3S)-3-hydroxypyrrolidine-1-carboxylate, THF,
0°C, 3 h, NH4Cl, 82%; (b) diethyl ether, conc. HCl, 0°C, quant.; (c) load onto SCX in methanol, elute with
1 M NH3 in MeOH, 95%; (d) {2-(6-chloropyrimidin-4-yl)-5-methyl-pyrazol-3-ol}: (6-chloropyrimidin-4-
yl)hydrazine and methyl 3-oxobutanoate 2-propanol, reﬂux 90 min, 14%; (e) 2-(6-chloropyrimidin-4-yl)-
5-methyl-pyrazol-3-ol and product from c, NMP, DIPEA, 30 min at 100°C, 89%, 1H NMR (400 MHz;
DMSO-d6, ): 8.84 (s, 1H), 8.46 (d, 1H), 8.42 (d, 1H), 7.77 (dd, 1H), 7.08 (bs, 1H), 5.59 (bs, 1H), 5.24 (bs, 1H),
3.95 (dd, 1H), 3.81 (bs, 2H), 3.68 (dq, 1H), 2.43 to 2.50 (m, 1H), 2.35 to 2.40 (m, 1H), 2.19 (s, 3H).
ZAC623 {3-[(3S)-1-[6-(5-amino-3-methyl-pyrazol-1-yl)pyrimidin-4-yl]pyrrolidin-3-yl]oxypyri-dine-
4-carbonitrile} synthesis pathway: (a) tert-butyl-N-aminocarbamate, DIPEA, THF, rt ¡ reﬂux, 98%; (b)
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pyrrolidine from ZAC989-c, DIPEA, NMP, 120 °C, 1 h, 71%; (c) (i) TFA, DCM, rt, 30 min, (ii) load onto
SCX in methanol, elute with 0.5 M NH3 in MeOH, quant.; d, Z-3-amino-but-2-enenitrile, AcOH, EtOH,
80°C 4 h, 85%. 1H NMR (500 MHz; DMSO-d6, ): 8.80 (s, 1H), 8.36 (d, 1H), 8.30 (d, 1H), 7.78 (dd, 1H),
6.84 (s, 1H), 6.65 (bs, 1H), 5.54 (bs, 1H), 5.21 (s, 1H), 3.81 (bs, 2H), 3.61 (bs, 2H), 2.25 to 2.46 (bs, 2H),
2.07 (s, 3H).
Fungal isolates and growth conditions. Fungal isolates used in this study were purchased from
either the ATCC, DSMZ (Germany), or Danish National Serum Institute (SSI), with the exception of C.
glabrata strain Cg003, which was a kind gift from Julius Subik, Comenius University in Bratislava, Slovak
Republic. C. glabrata Cg003 is clinical isolate 3 previously used by Berila and Subik and was characterized
to be resistant to ﬂuconazole and itraconazole via overexpression of the multidrug resistance efﬂux
pumps Cdr1p and Cdr2p (34). Aspergillus terreus isolate At070 was a kind gift from Herning Hospital,
Denmark. The Aspergillus fumigatus strains AF14, AF54, AF48, AF721, and AF731 have been described
previously (3, 24, 27).
Candida albicans SC5314, C. glabrata ATCC 90030 and Cg003, Candida krusei ATCC 6258, Candida
parapsilosis ATCC 22019, and Candida tropicalis Ct016 were grown in Sabouraud broth (40 g/liter of
D-glucose, 10 g/liter of peptone [pH 5.6]) or YPD (10 g/liter of yeast extract, 20 g/liter of Bacto peptone,
20 g/liter of glucose) liquid medium to mid-log phase, aliquoted into a ﬁnal concentration of 20%
(vol/vol) glycerol, and maintained as frozen stocks at 80°C. Frozen stocks of the mold isolates (A.
fumigatus ATCC 13073, Aspergillus ﬂavus ATCC 15547, A. terreus At070, Rhizopus oryzae ATCC 34965, and
Rhizopus microsporus ATCC 66276) and Mucor indicus ATCC MYA-4678 were prepared by harvesting
spores from 7-day-old potato glucose agar plates in phosphate-buffered saline (PBS) containing 0.1%
Tween 80 and aliquoting these spores in the presence of glycerol at a ﬁnal concentration of 20% (vol/vol).
SD medium without zinc (SDwoz; 1.71 g/liter of YNB-ZnSO4 [1541; Sunrise Science], 2% glucose, 5
g/liter of ammonium sulfate) was prepared in a glass beaker washed with 0.37% HCl and rinsed with
water. The pH was adjusted to 7.0 with NaOH, and the medium was made sterile by ﬁltration.
Dissociation constant determination. The dissociation constant (Kd) of zinc to zinc-attenuating
compounds was determined at room temperature using FluoZin-3 (F24194; Thermo Fisher Scientiﬁc),
which has a Kd (FluoZin-3–Zn2) of 15 nM (35). Testing buffer consisted of PBS (pH 7.4) with 200 nM ZnCl2
and 500 nM FluoZin-3. In a microtiter plate, 98 l of testing buffer was mixed with 2 l of compound
at a range of concentrations to determine the half-maximal inhibitory concentration (IC50). Testing plates
were incubated for 2 min before being read at an excitation wavelength of 485 nm and an emission
wavelength of 516 nm with a Fluoroskan Ascent microplate ﬂuorometer (Thermo Fisher Scientiﬁc). The
Kds were calculated using the equation Kd (compound-Zn2)  IC50/(1  [FluoZin-3]/Kd, FluoZin-3–Zn2)
(36).
Potentiometric titration. Potentiometric measurements were carried out in DMSO-water (70:30,
vol/vol) at 25°C as described previously (22). Titrations were performed with a pH meter (Denver
Instruments) utilizing a glass electrode with AgCl reference ﬁlled with 3.0 M KCl. The electrode was
equilibrated in DMSO-water (70:30, vol/vol) for at least 1 h before use. All experiments were performed
at a constant ionic strength (0.1 M NaClO4). Three milliliters of a solution containing 1 mM compound was
titrated with 0.3 M NaOH by manual additions in 1- to 5-l increments with magnetic stirring. The
metal-ligand binding constants were obtained from titrations of the metal complex solutions prepared
in a 1:2 metal-to-ligand ratio. The titration data were reﬁned by the nonlinear least-squares reﬁnement
program Hyperquad2013 (37) to determine the deprotonation and stability constants.
Antifungal susceptibility testing. Antifungal susceptibility testing was carried out as described
previously (38, 39), with a few modiﬁcations. Brieﬂy, for each yeast or mold growth inhibition assay,
frozen stocks of yeast cells or spores were diluted to a ﬁnal concentration of 0.5 	 105 to 2.5 	 105
CFU/ml in sterile water. ZAC989, ZAC307, and ZAC623 were dissolved in DMSO to 10 mM stocks from
which half-log serial dilutions were prepared. Growth assays were subsequently performed by pipetting
3 l of compound dissolved in DMSO (giving a ﬁnal concentration of 1.5% DMSO), 100 l of cell-spore
suspension, and 97 l of 2	 RPMI medium (20.8 g/liter of RPMI 1640 medium, 69.06 g/liter of
morpholinepropanesulfonic acid [MOPS], 36 g/liter of glucose) into a microtiter plate that was incubated
for 24 h (yeasts) or 48 to 72 h (molds) at 34°C. Fungal growth was determined spectrophotometrically
by optical density reading of each well at a wavelength of 492 nm on a Victor X5 (Perkin-Elmer) plate
reader. The MIC was deﬁned as the lowest compound concentration that resulted in at least 50% growth
inhibition for yeast, which corresponded to a prominent decrease in visible growth. For the molds, the
MIC was deﬁned as the lowest concentration of the compound that resulted in no visible growth.
Standard errors between repeated experiments were generally below 5%. The growth effect of exoge-
nous addition of various divalent metals was evaluated by performing the antifungal susceptibility assay
in the presence of 5 M ZAC989 or ZAC307 and with increasing concentrations (0.003 to 50 M) of
ZnSO4, CuSO4, (NH4)2Fe(SO4)2, MgCl2, and CaCl2. The minimal fungicidal concentration (MFC) was the
minimum concentration that resulted in no CFU and was determined after the MIC by plating 5 l of the
mixture from wells with no visible growth onto YPD agar plates followed by 24 h of incubation at 30°C.
Growth capacity experiments with A. fumigatus strains AF14, AF54, AF48, AF732, and AF731 were
performed in 24-well ﬂat-bottomed tissue culture plates (35-3047; Falcon). A stock solution of 10 mM
TPEN (P4413; Sigma) was prepared in pure ethanol. For these experiments, 5 mM stock solutions of
ZAC307 and ZAC989 were prepared by dissolving each compound in 80% (vol/vol) ethanol. A 0.5 M stock
solution of Na2EDTA·2H2O (1.08421.1000; Merck) was prepared in sterile water. A 1	 stock solution (10.4
g/liter) of RPMI 1640 medium (R8755; Sigma) supplemented with 10 M FeSO4·7H2O, 1 M CuSO4·5H2O,
and 1 M MnCl2·H2O (sRPMI) was prepared under aseptic conditions and used as standard culture
medium. In each well, 1 ml of culture medium containing sRPMI medium, Tween 20, ethanol (or the
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speciﬁed compound dissolved in 80% ethanol), and 105 conidia was dispensed to achieve ﬁnal concen-
trations of 0.7	, 0.05% (vol/vol), 1.2% (vol/vol), and 105 conidia/ml, respectively. Plates were incubated
for 44 h at 37°C in a humid atmosphere. To quantitate mycelial growth, each plate was scanned in an
Agfa SnapScan 1236s scanner, and the intensity of the wells was quantiﬁed using the open-source image
processing program Image J2. The data were represented and analyzed with Prism software 7.0.
Time-kill assay. C. albicans SC5314 cells (105 CFU/ml) were incubated in 10 ml of RPMI medium at
30°C with gentle agitation (150 rpm) in the presence of EDTA (15 M), TPEN (10 M), ZAC989 (10 M),
or AMB (0.5 M). At the desired time points (0, 3, 5.5, and 24 h), a 100-l aliquot was removed for each
test condition and serially diluted (10-fold) in saline (0.9% NaCl), and 30 l of each dilution was plated
on YPD agar plates. The colony count on each YPD plate was determined after incubation at 30°C for 48
h (40). C. albicans cells treated with DMSO (1%, vol/vol) served as a control.
Resistance study. The propensity for resistance development was investigated as also described
previously (41), but with the following modiﬁcations. C. albicans was repeatedly exposed to either
ZAC989 or ZAC307 in 1-ml cultures in SDwoz medium with a starting inoculum that had an optical
density at 600 nm (OD600) of 0.007. A compound concentration that resulted in 90% growth inhibition
was selected for these experiments (3.6 g/ml for ZAC989, 2.8 g/ml and 5.6 g/ml for ZAC307, and 0.5
g/ml and 1.0 g/ml for ﬂuconazole). Over a 36-day period, culture aliquots of 100 l were periodically
(every 1 to 2 days) transferred (passaged) to new culture tubes with 900 l of fresh medium and fresh
compound. The cells were incubated at 30 °C with gentle agitation (150 rpm), and the OD600 of cultures
was monitored throughout the period to ensure that the numbers of cells exposed to compounds were
comparable across treatments for each passage. Cells were passaged a total of 22 times, and cultures
were periodically tested for antifungal susceptibility by following the protocol for antifungal suscepti-
bility testing, as described above.
Zinbo-5 assay. C. albicans BWP17 was grown overnight in YPD medium at 30°C and 150 rpm. The
cells were pelleted, washed in PBS buffer (D8537; Sigma) 3 times, and resuspended to an OD600 of 2.0.
Two microliters of compound in DMSO was mixed with 100 l of cell suspension and incubated statically
for 1, 8, or 24 h at 30°C in a 96-well black plate. Thirty minutes before the end of the incubation period,
100 l of 10 M Zinbo-5 (sc-222425; Santa Cruz Biotechnology) in PBS buffer was added. The afﬁnity
constant of this probe for zinc is 2.2 nM (23). The plate was then read on a plate reader (FLUOstar Optima;
BMG Lab Technologies) with excitation at 355 nm and emission at 485 nm. The decrease in Zinbo-5
ﬂuorescence was calculated relative to the untreated DMSO control.
RNA isolation from Aspergillus fumigatus. A total of 1.5	 106 conidia of the wild-type strain (AF14)
were inoculated into 20 ml of 0.7	 sRPMI, 0.05% Tween 20, and 1.2% ethanol dispensed into 100-ml
culture ﬂasks pretreated with an overnight wash in 2 mM EDTA (pH 8.0) to minimize the presence of
metal traces, followed by a thorough washing with ultrapure Milli-Q water. The ﬂasks were subsequently
sterilized in an oven at 180°C. The cultures were incubated for 20 h at 37°C and 200 rpm before the
following were added: (i) pure ethanol to a ﬁnal concentration of 1.2% (vol/vol) (as a reference for the
transcription proﬁles of all genes under zinc-limiting conditions), (ii) 1.2% ethanol plus a solution of
ZnSO4 to a ﬁnal concentration 20 M zinc (as a reference for the transcription proﬁles of all genes under
zinc-replete conditions following the zinc shift), (iii) 1.2% ethanol plus a solution of EDTA to a ﬁnal
concentration of 500 M, (iv) 1.2% ethanol plus a solution of TPEN to a ﬁnal concentration of 10.6 g/ml,
and (v) a 5 mM solution of each test compound (ZAC307 or ZAC989) dissolved in 80% ethanol to a ﬁnal
concentration of 75 M and 1.2% ethanol (which correspond to 21 g/ml and 27 g/ml, respectively).
After compound addition, cultures were incubated for 2 h at 37°C and 200 rpm and mycelia were
harvested by ﬁltration through ﬁlter paper, washed twice with sterile waterm and snap-frozen in liquid
nitrogen. After grinding of the mycelia in the presence of liquid nitrogen, total RNA was extracted using
an RNeasy plant minikit (74904; Qiagen) according to the manufacturer’s instructions. RNA was eluted in
50 l of RNase-free water. RNA integrity was veriﬁed on 0.8% agarose gels stained with ethidium
bromide. RNA was stored at 80°C until use.
RT-qPCR. Total RNA concentration and quality were determined by UV spectrometry (NanoDrop
ND1000 spectrophotometer; Thermo Fisher Scientiﬁc), and all samples were brought to a ﬁnal concen-
tration of 150 ng/l. Total RNA (1.5 g) was treated with RQ1 DNase I (M610; Promega) and subsequently
assessed by conventional PCR for the complete absence of genomic DNA (gDNA). Subsequently, 1 g of
DNase-treated RNA was reversed transcribed using SuperScript II reverse transcriptase (18064-014;
Invitrogen, Thermo Fisher Scientiﬁc), with random hexamers (11034731001; Roche Diagnostics) as
primers. Prior to qPCRs, cDNA samples were diluted 1:3 in water, except in the case of reactions against
the 18S rRNA, for which samples were diluted 1:1,200 in water. qPCRs were performed on a Bio-Rad
CFX96 instrument. A typical qPCR mixture (10 l) contained 13.5 ng of cDNA (32 pg when the qPCR was
for 18S rRNA), a speciﬁc pair of primers (150 nM ﬁnal concentration), and the SYBR premix Ex Taq
(RR420A; TaKaRa). Primers used for qPCR are listed in Table 5. For all qPCRs, 40 cycles were performed
using the following cycling conditions: denaturation at 95°C for 10 s, annealing at 59°C for 20 s, and
extension at 72°C for 20 s. The relative expression ratio (rER) was calculated using the threshold cycle
(2ΔΔCT) method (42) using the expression level of the 18S rRNA as an internal reference.
Human hepatocyte (HepG2) proliferation assay. In each well of a 96-well tissue culture plate
(GR-655180; Grenier), 10,000 human hepatocytes (HepG2) (85011430; Sigma) were plated in 200 l of
growth medium (Eagle’s minimum essential medium [M2279; Sigma]) supplemented with 2 mM
L-glutamine (03-020-1B; Biological Industries), 1% nonessential amino acids (XC-E1154/100; Biosera), and
10% fetal bovine serum (BI-04-007-1A; Biological Industries), and plates were incubated overnight at 37°C
and 5% CO2. The following day, fresh growth medium plus 2 l of compound in DMSO was added. The
plate was incubated for a further 24 h or 72 h at 37°C and 5% CO2. The medium was then replaced with
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100 l of freshly prepared 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt
(XTT) sodium salt solution (0.5 mg/ml of XTT; X4251; Sigma) in RPMI 1640 (R7509; Sigma-Aldrich) with
3.83 g/ml of phenazine methosulfate (P9625; Sigma-Aldrich) and incubated 2 to 3 h at 37°C and 5% CO2
(43). The color reaction was measured on Victor X5 plate reader (Perkin-Elmer) at OD450, and the
half-maximal effective concentration (EC50) was calculated. Tamoxifen (85256; Sigma) was used as a
positive-control compound.
In vivo fungal kidney burden candidiasis model. A murine model of systemic candidiasis was
established according to a previously described method (44). BALB/c mice were infected with a 0.1-ml
inoculum (1 	 105 to 5 	 105 CFU) of Candida albicans SC5314 cells by the intravenous route on day 0.
Compounds were tested at doses of 60 mg/kg. Administration of compound was initiated 24 h prior (day
1) to infection (day 0) by the intraperitoneal route, dosing twice a day for 4 days (day 1 to day 2).
ZAC307 was also evaluated with administration of the compounds given after the infection at day 0 (no
pretreatment) and following dosing twice a day for 3 days (days 0 to 2). Fluconazole was used as a
comparator drug. Six mice were used for each group, and the untreated control group was exposed to
the vehicle alone. ZAC989 and ZAC307 were formulated by taking 60 mg of compound and adding this
to 2 ml and 4 ml of 0.1 N NaOH, respectively. After mixing and sonication of the resulting solutions, 4
ml of puriﬁed water was added. The pH was adjusted to 9.0 with 0.1 N HCl solution, followed by the
addition of 90 mg of NaCl. The solutions were then diluted to 10 ml and ﬁltered through a 0.22-m
polyvinylidene diﬂuoride (PVDF) ﬁlter. Sample collection and processing were performed as follows.
Twelve hours after the last dose, all treated and untreated animals were sacriﬁced by cervical dislocation
and kidneys were collected in 3 ml of sterile normal saline. The samples were homogenized, serially
diluted, and plated on Sabouraud dextrose agar (SDA). SDA plates were incubated for 24 to 48 h at 35°C,
and CFU were enumerated and reported as log CFU/kidney. The endpoint was mean log CFU of fungi
in kidneys of treated animals compared to that of untreated animals. The study was conducted in
conformance with an application submitted to the Committee for the Purpose of Control and Supervi-
sion of Experiments on Animals (CPCSEA), New Delhi, India, after approval from the Institutional Animal
Ethics Committee (IAEC).
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